Updated February 19, 2017. There's no right way to study in college. Even students who have the same majors and take the same classes won't need to spend the same amount of time on coursework, because everyone has their own way of learning.
New Arthritis Drug Xeljanz Gets FDA Approval. Nov. 6, 2012 -- The FDA has approved Pfizer's Xeljanz (tofacitinib), a first-of-its-kind treatment for rheumatoid arthritis. Xeljanz is approved for use by patients not helped by methotrexate, the usual first treatment for RA. It's a pill taken twice a day. Xeljanz is a type of drug called a Janus kinase or JAK inhibitor. Blocking JAK mutes the inflammation responses responsible for RA.
The U.S. Food and Drug Administration (FDA) recently approved Praluent (alirocumab)â and Repatha (evolocumab)â, the first cholesterol-lowering injection treatments in the new class of PCSK9 inhibitors. Theyâre designed to be used in combination with statin therapy and dietary changes. Praluent and Repatha are for adults with heterozygous familial hypercholesterolemia (HeFH), an inherited condition that causes high levels of LDL cholesterol in the blood, and those with clinical cardiovascular disease.